At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Parcopa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial
In Brief
A Phase 4 clinical trial evaluating Parcopa and carbidopa-levodopa (Sinemet) for Parkinson's Disease. Completed, enrolled 20 participants across 1 site.
Detailed Summary
To find out if a single dose of Parcopa®, a form of levodopa that dissolves in your mouth, works faster than regular oral levodopa which is swallowed, in fluctuating PD patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsUCB Pharma
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedJan 2008
Primary CompletionOct 2008
Study CompletionNov 2008
TodayJul 2026
First PostedJan 10, 2008
Enrollment StartOct 1, 2006
Primary CompletionOct 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.5 years ago
Interventions
Parcopadrug
at subjects current stable dose of comparator
carbidopa-levodopa (Sinemet)drug
at subjects current stable dose